There is a general consensus that in the context of the antitumor immune response, the frequency of CD8+ lymphocytes and their memory T cell subsets correlates positively with smaller tumor size, lower disease stages, less lymph node involvement, and a generally better prognosis or survival in most types of cancer, e.g. breast carcinoma [14, 16–22]. Here, CD8A is linked to cancer.